Nurix Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRIX research report →
About the company
Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
- CEO
- Arthur T. Sands
- IPO
- 2020
- Employees
- 314
- HQ
- Brisbane, CA, US
Price Chart
- Market Cap
- $2.08B
- P/E
- -7.59
- P/S
- 28.94
- P/B
- 5.49
- EV/EBITDA
- -7.53
- Div Yield
- 0.00%
- Gross Margin
- -139.43%
- Op Margin
- -439.26%
- Net Margin
- -411.37%
- ROE
- -64.21%
- ROIC
- -57.63%
- Revenue
- $83.98M · 53.95%
- Net Income
- $-264,457,000 · -36.62%
- EPS
- $-3.05 · -5.90%
- Op Income
- $-285,666,000
- FCF YoY
- -44.88%
- 52W High
- $24.88
- 52W Low
- $8.20
- 50D MA
- $17.52
- 200D MA
- $15.65
- Beta
- 1.87
- Avg Volume
- 1.99M
Get TickerSpark's AI analysis on NRIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | Ring Christine | other | 5,787 |
| Jul 2, 26 | Ring Christine | other | 5,787 |
| Jul 2, 26 | Ring Christine | other | 5,221 |
| Jul 2, 26 | Ring Christine | sell | 11,008 |
| Jul 2, 26 | Ring Christine | other | 5,221 |
| Jun 25, 26 | Hansen Gwenn | sell | 5,394 |
| Jun 25, 26 | Ring Christine | other | 15,602 |
| Jun 25, 26 | Ring Christine | other | 15,602 |
| Jun 25, 26 | Ring Christine | other | 13,333 |
| Jun 25, 26 | Ring Christine | sell | 28,935 |
Our NRIX coverage
Recent articles, reports, and earnings notes.
No research on NRIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRIX report →Similar companies
Peers in the same neighborhood.